New Alzheimer's drug repairs DNA damage and reduces brain inflammation
Researchers at King's College London have identified that an existing drug, KCL-286, shows promise in treating Alzheimer's disease by repairing DNA damage and reducing inflammation. The drug has already passed Phase 1 safety trials, potentially accelerating the development timeline for a disease-modifying therapy.
Researchers at King's College London have identified a promising new strategy for tackling Alzheimer's disease by targeting several of the disease's earliest biological changes at the same time. Their study found that KCL-286, an experimental drug originally developed for spinal cord injury that has already passed Phase 1 safety trials, reduced multiple hallmarks of Alzheimer's in a mouse model.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in